Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. - A total of 373 stocks (77.9%) in the sector rose last week, while 97 stocks (20.3%) declined. The top five gainers were Shuyou Shen (60.41%), Huason Pharmaceutical (41.97%), Changshan Pharmaceutical (35.91%), Huana Pharmaceutical (32.62%), and Yifang Biological (30.51%) [4][27]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the approval of 11 innovative drugs by the National Medical Products Administration (NMPA) on May 29, which enhances treatment options for patients and showcases the increasing innovation capability of China's pharmaceutical industry [5][29]. - The 2025 American Society of Clinical Oncology (ASCO) annual meeting showcased several domestic innovative drug projects, indicating that local companies are gaining international recognition for their innovative capabilities [5][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector as it is the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. Additionally, it recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][35]. - Recommended stocks include Beida Pharmaceutical, Te Bao Biological, Qianhong Pharmaceutical, Ling Rui Pharmaceutical, and Lao Bai Xing. Stocks to watch include Kelong Pharmaceutical, Rongchang Biological, Kaili Medical, Huaxia Eye Hospital, and Baipu Sais [6][35].

华森制药盘中涨停，已连收5个涨停板，截至9:58，该股报22.69元，换手率9.63%，成交量2976.13万 股，成交金额6.56亿元，涨停板封单金额为1.28亿元。连续涨停期间，该股累计上涨61.00%，累计换手 率为38.11%。最新A股总市值达94.75亿元，A股流通市值70.09亿元。 龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%上榜龙虎榜2次，买卖居前营业部 中，机构净买入371.59万元，深股通累计净卖出2740.42万元，营业部席位合计净买入1.21亿元。 4月25日公司发布的一季报数据显示，一季度公司共实现营业总收入2.39亿元，同比增长4.62%，实现净 利润0.40亿元，同比增长0.01%。（数据宝） 近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.05.30 | 10.03 | 4.42 | 7288.88 | | 2025.05.29 | 10.01 | 9.24 | 9532.85 | | 2025.05.28 | 9.97 | 11.94 | 599 ...

证券代码：002907 证券简称：华森制药 公告编号：2025-050 重庆华森制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况的说明 （三）近期公司生产经营情况正常，公司已披露的经营情况、内外部经营环 境未发生重大变化。 （四）经核查，公司、控股股东和实际控制人不存在关于公司的应披露而未 披露的重大事项，或处于筹划阶段的重大事项。 （五）经核查，控股股东、实际控制人在股票异常波动期间不存在买卖公司 股票的情形。 三、是否存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据深圳证券交易所《深圳证券交 易所股票上市规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹 划、商谈、意向、协议等；董事会也未获悉本公司有根据深圳证券交易所《深圳 证券交易所股票上市规则》等有关规定应予以披露而未披露的、对本公司股票及 其衍生品种交易价格产生较大影响的信息；公司前期披露的信息不存在需要更正、 补充之处。 重庆华森制药股份有限公司（以下简称"公司"）股票（证券简称：华森制 药，证券代码：0 ...

智通财经6月2日电，华森制药(002907.SZ)公告称，公司股票于2025年5月29日、5月30日连续两个交易 日内收盘价格涨幅偏离值累计达到20.71%，属于股票交易异常波动情况。经核实，公司前期所披露的 信息不存在需要更改、补充之处，未发现近期公共媒体报道了可能或已经对公司股票交易价格产生较大 影响的未公开重大信息，生产经营情况正常，内外部经营环境未发生重大变化，公司、控股股东和实际 控制人不存在关于公司的应披露而未披露的重大事项，或处于筹划阶段的重大事项。控股股东、实际控 制人在股票异常波动期间不存在买卖公司股票的情形。公司不存在违反信息公平披露的情形。 华森制药：目前经营情况正常 不存在应披露而未披露的重大事项 ...

Group 1: Company Performance and Market Position - The revenue of traditional Chinese medicine (TCM) increased by 24.49% year-on-year, with the five key TCM products growing by 31.44% year-to-date [3] - Sales revenue of Ganqi Bingmei Tablets rose by 38.84% during the reporting period, and by 54.36% year-to-date [3] - The company has received 32 recommendations from authoritative textbooks, clinical guidelines, and expert consensus for its five key TCM products, indicating strong market and clinical recognition [3] Group 2: Sales Strategy and Market Development - The current sales strategy focuses primarily on public hospitals, which account for approximately 70% of the market, while also developing grassroots hospitals, private hospitals, retail pharmacies, and e-commerce platforms [4] - The company aims to increase its market share in existing markets while exploring new growth opportunities through a multi-channel approach [4][7] Group 3: Research and Development Progress - As of May 2025, the company has integrated its R&D pipeline with Chengdu Aorui Pharmaceutical Co., gaining control over 7 innovative drug projects targeting various cancers and autoimmune diseases [5] - The lead project, ORIC-1940, is currently in clinical phases Ia/Ib, with plans to submit IND applications for two additional projects by the end of this year and the first quarter of next year [5][6] Group 4: Response to Market Challenges - The company acknowledges that centralized procurement has a significant impact on existing products but limited effect on new varieties, and it is exploring diversified development strategies to mitigate price reduction risks [6][7] - The company is actively expanding its product line to include special medical foods and nutrition products, enhancing its market competitiveness [7]

一、行情回顾 市场全天震荡调整，创业板指领跌。创新药概念逆势大涨，睿智医药、海南海药、哈三联等多股涨停。猪肉、鸡肉股拉升，巨星农牧、湘佳股份封板。银行 股继续走强，杭州银行、成都银行创历史新高。下跌方面，高位股集体大跌，王子新材等多股跌停。个股跌多涨少，沪深京三市超4100股飘绿，今日成交 1.16万亿。 根据渤海证券统计，本周多款创新药获批上市，包括恒瑞医药的瑞康曲妥珠单抗、磷罗拉匹坦帕洛诺司琼、苹果酸法米替尼，复星医药的枸橼酸伏维西利、 芦沃美替尼，百济神州的泽尼达妥单抗，泽璟制药的盐酸吉卡昔替尼等，同时美国关税政策边际变化带动 CXO 板块快速反弹。 2025年美国临床肿瘤学会（ASCO）即将于当地时间5月30日至6月3日在美国芝加哥召开。 | 股票名称 | | 最新价 = | 涨跌幅 = | 涨停时间 = | 换手率 = | 流通市值 = | | | --- | --- | --- | --- | --- | --- | --- | --- | | 华森制药 | 4天4板 | 20.63 | +10.03% | 09:32:48 | 4.42% | 63.72亿 | 公司旗下5个产品完 美拉唑碳酸氢钠 ...

Core Viewpoint - The Chinese medicine sector is experiencing a collective pullback in the A-share market, while the Chinese Medicine ETF (560080) has shown resilience, rising nearly 1% and reaching a new high since January 8 of this year [1] Company News - Huawen Pharmaceutical announced the approval from the Singapore Health Sciences Authority for the registration of its traditional Chinese medicine, Tongxie Ning Granules, for sale in Singapore. This marks the fourth overseas registration for the company, following previous approvals for other products [3] - Tongxie Ning Granules is the first natural plant medicine globally for treating IBS-D, demonstrating significant efficacy and high safety, with the ability to prevent recurrence [3] Industry Insights - Huafu Securities indicates that the pressure from high base numbers in the Chinese medicine sector has cleared in the first quarter, with expectations for gradual improvement in performance from Q2 to Q3 of 2025 due to low valuation and low allocation [4] - The firm identifies three major catalysts for the Chinese medicine industry: 1. Accelerated approval and market entry of innovative Chinese medicines, with 9 new drugs approved in 2023 and an expected increase to 16 in 2024 [6] 2. Anticipated adjustments to the essential drug catalog, which will favor innovative Chinese medicines, with a significant increase in the number of traditional Chinese medicine varieties included [6] 3. A decline in the prices of Chinese medicinal materials and expectations for product price increases, which could enhance performance for companies using these materials [7] Key Indicators - The core indicators for the Chinese medicine sector include flu data and the price index of medicinal materials. The flu cases have returned to normal levels, and the pressure on revenue growth for most companies is expected to ease from Q2 2025 [8] - The price index of medicinal materials has been declining since mid-July 2024, with common materials like Lianqiao and Dangshen also showing price decreases, which may alleviate gross margin pressures for companies in 2025 [8]

Pharmaceutical Sector - Huason Pharmaceutical has achieved a 10.03% increase over four consecutive trading days, driven by solid beverage products [2] - Rongzhishiyao has seen a 19.98% rise over two days, attributed to its food and beverage innovations [2] - Qianhong Pharmaceutical recorded a 10.03% increase over three days, linked to its innovative drug offerings [2] - Hainan Haiyao debuted with a 10.07% rise, supported by its innovative drug initiatives [2] - NuoSilande and Warner Pharmaceuticals have both shown significant gains of 22.82% and 19.98% respectively, due to their innovative drug developments [3] Digital Currency Sector - Yuyin Co. has increased by 10.07% over three days, driven by developments in digital currency [5] - Hailian Maohui has also seen a 10.04% rise over two days, attributed to digital currency trends [6] - The Hong Kong Legislative Council passed the Stablecoin Bill, which is expected to lead to the official launch of stablecoins by the end of this year [4] Autonomous Vehicles Sector - Debon Logistics has achieved a 9.99% increase over four consecutive days, driven by developments in unmanned logistics vehicles [8] - Zhongli Co. has seen a 10.00% rise over two days, also linked to the unmanned logistics vehicle sector [8] - Xiaoma Zhixing announced a strategic cooperation with Guangzhou Public Transport Group to collaborate on autonomous driving and logistics services [7] Commercial Aerospace Sector - Zhongheng Design debuted with a 9.98% increase, attributed to developments in the commercial aerospace sector [10] - Zhongtian Rocket also saw a 10.00% rise, linked to advancements in commercial aerospace [10] Other Notable Stocks - Palm Co. has achieved a 10.00% increase over ten days, reflecting strong market interest [15] - Debon Co. has recorded a 9.99% rise over four consecutive days, indicating sustained investor confidence [15]

Group 1 - The innovative drug concept has become active again, with companies like Ruizhi Pharmaceutical reaching a 20% limit up, and others like Kexing Pharmaceutical and Shutaishen rising over 15% [1] - Huason Pharmaceutical has achieved a continuous limit up for four trading days, receiving approval from the Health Sciences Authority of Singapore for its traditional Chinese medicine product, Tongxie Ning granules, which is the first natural plant drug for treating IBS-D globally [1][2] - Tongxie Ning granules are derived from a classic formula and are noted for their efficacy in treating IBS through multiple pathways and targets, with high safety and significant effectiveness [1] Group 2 - Huason Pharmaceutical's recent approval marks the fourth product to achieve overseas registration, enhancing the company's international market recognition [2] - Although the product has not yet been commercialized overseas, successful commercialization could positively impact the company's performance, though it faces uncertainties from market policies, exchange rate fluctuations, and competition [2] - Shutaishen has seen a cumulative increase of over 140% in the last nine trading days, with attention on its subsidiary's application for priority review of the injectable STSP-0601, which is currently in the public notice period [2]

智通财经5月30日电，创新药概念股盘中持续走强，万邦德、康弘药业、千红制药、华森制药、哈三 联、联化科技、海南海药、华纳药厂、睿智医药等10余股涨停，舒泰神、科兴制药、冠昊生物等涨超 10%。 创新药概念股持续走高 万邦德等10余股涨停 ...